5 Best Low Price Pharma Stocks To Buy Now

3. Veru Inc. (NASDAQ:VERU)

Number of Hedge Fund Holders: 13

Share Price as of October 17: $10.86

Veru Inc. (NASDAQ:VERU) is a Florida-based oncology biopharmaceutical company that focuses on developing medicines for the management of cancer. On September 20, Oppenheimer analyst Leland Gershell noted that the date of the FDA Advisory Committee meeting to discuss Veru Inc. (NASDAQ:VERU)’s sabizabulin was postponed to November 9 from October 6. From his discussion with Veru Inc. (NASDAQ:VERU)’s management, the analyst told investors that the FDA’s meeting was delayed to allow the agency additional time to review the relevant material, including clinical trial results. While this delays the potential start of U.S. sales to at least November, his optimism for Emergency Use Authorization “remains unchanged.” The analyst has an Outperform rating on Veru Inc. (NASDAQ:VERU) shares.

According to Insider Monkey’s Q2 data, 13 hedge funds were long Veru Inc. (NASDAQ:VERU), up from 9 funds in the prior quarter. Peter Kolchinsky’s RA Capital Management is the leading stakeholder of the company, with 7.90 million shares worth $89.2 million.